Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $252.4 million.

  • Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity rose 165.76% to $252.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $795.6 million, marking a year-over-year increase of 74.81%. This contributed to the annual value of $162.9 million for FY2024, which is 5.46% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Liabilities and Shareholders Equity stood at $252.4 million for Q3 2025, which was up 34.74% from $187.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity ranged from a high of $252.4 million in Q3 2025 and a low of $70.3 million during Q2 2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $157.2 million, with a median of $159.7 million in 2023.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity plummeted by 55.99% in 2024, and later spiked by 166.49% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Liabilities and Shareholders Equity (Quarterly) stood at $154.5 million in 2023, then increased by 5.46% to $162.9 million in 2024, then spiked by 165.76% to $252.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $252.4 million for Q3 2025, versus $187.4 million for Q2 2025 and $192.9 million for Q1 2025.